Success Metrics

Clinical Success Rate
100.0%

Based on 18 completed trials

Completion Rate
100%(18/18)
Active Trials
1(5%)
Results Posted
78%(14 trials)

Phase Distribution

Ph phase_4
5
25%
Ph phase_3
10
50%
Ph phase_1
1
5%
Ph not_applicable
2
10%
Ph phase_2
2
10%

Phase Distribution

1

Early Stage

2

Mid Stage

15

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
1(5.0%)
Phase 2Efficacy & side effects
2(10.0%)
Phase 3Large-scale testing
10(50.0%)
Phase 4Post-market surveillance
5(25.0%)
N/ANon-phased studies
2(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

18 of 18 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

20

all time

Status Distribution
Active(1)
Completed(18)
Other(1)

Detailed Status

Completed18
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (5.0%)
Phase 22 (10.0%)
Phase 310 (50.0%)
Phase 45 (25.0%)
N/A2 (10.0%)

Trials by Status

unknown15%
active_not_recruiting15%
completed1890%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT01762046Phase 1

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

Completed
NCT06168812Phase 2

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Active Not Recruiting
NCT02608177Not Applicable

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

Completed
NCT01698775Phase 3

A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Completed
NCT00885352Phase 3

Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Completed
NCT00509262Phase 3

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Completed
NCT00509236Phase 3

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

Completed
NCT00350779Phase 3

Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

Completed
NCT00116831Phase 3

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

Completed
NCT01951651Phase 4

Effect of Exenatide on Liver and Heart Fat and Inflammation

Completed
NCT00095056Phase 3

An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)

Completed
NCT00660907Phase 3

Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

Completed
NCT00856284Phase 3

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Completed
NCT00707993Phase 3

Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics

Completed
NCT01758471Phase 4

Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes

Unknown
NCT01020123Phase 2

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

Completed
NCT00513630Phase 4

Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease

Completed
NCT01082796Not Applicable

Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects

Completed
NCT00347100Phase 4

Insulin Glargine in Type 2 Diabetic Patients

Completed
NCT00732524Phase 4

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20